Dragonfly Therapeutics Inc. and Bristol Myers Squibb have entered into a definitive agreement under which Bristol Myers Squibb will be granted the global exclusive license to Dragonfly’s interleukin-12 investigational immunotherapy program, including its extended half-life cytokine DF6002.
Elizabeth Comen originally set out to write a book about the wellness industry, but ended up writing a different book altogether.
